Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
68562-41-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human insulin-like growth factor 1 (IGF-1)growth factor replacement biologic
Mechanism of action
Binds and activates the IGF-1 receptor, stimulating cellular growth, differentiation and metabolism. It provides replacement of deficient IGF-1 activity in severe primary IGF-1 deficiency.
Indications / reported uses
Treatment of growth failure in paediatric patients aged 2 years and older with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralising antibodies to growth hormone; not a substitute for growth hormone in other causes of short stature
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Mecasermin Environmental Risk Assessment (ERA) (the Mecasermin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.